scispace - formally typeset
M

Margarita Kirienko

Researcher at Humanitas University

Publications -  67
Citations -  1997

Margarita Kirienko is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & PET-CT. The author has an hindex of 21, co-authored 58 publications receiving 1280 citations. Previous affiliations of Margarita Kirienko include University of Milano-Bicocca.

Papers
More filters
Journal ArticleDOI

Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics

TL;DR: The transfer learning from the well-known drug development process, with some specific adaptations to the image mining discipline could represent the most effective way for radiomics and AI algorithms to become the standard of care tools.
Journal ArticleDOI

PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology

TL;DR: A comprehensive review of literature describing the state-of-the-art of FDG-PET/CT texture analysis in NSCLC is provided, suggesting a proposal for harmonization of methodology.
Journal ArticleDOI

Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery

TL;DR: A radiomic signature, for either CT, PET, or PET/CT images, has been identified and validated for the prediction of disease-free survival in patients with non-small cell lung cancer treated by surgery.
Journal ArticleDOI

Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions

TL;DR: PET radiomics features were able to differentiate between primary and metastatic lung lesions and showed the potential to identify primary lung cancer subtypes.
Journal ArticleDOI

11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients

TL;DR: High-dose hypofractionated 11C-choline PET/CT-guided HTT with SIB is well tolerated and is associated with a high early biochemical response rate, which is valuable for planning and monitoring HTT in LN relapse after primary treatment.